Imatix pronounces $110 million underwriting providing

hAustin, Texas And T├╝bingenGermany, october 10, 2022 – Emetics N.V. (NASDAQ: IMTX, “Imetics”), a clinical-stage biopharmaceutical firm lively within the discovery and growth of T cell-redirecting most cancers immunotherapies, in the present day introduced that it’ll promote via an underwritten public providing. has agreed to 10,905,000 of its frequent shares at a value of $10,905,000 … Read more